Posts tagged Phase 3
Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20.

Read More
BTIG starts Clementia at buy

BTIG initiated coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with a “buy” rating and 12-month price target of $32, saying the company’s lead molecule, palovarotene, presents a plethora of promising possibilities. The stock closed at $16.01 on August 30.

Read More
BiondVax begins search for new chairman, to delist from TASE

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) announced that the board has formed a committee to identify a new chairman with relevant global experience to guide the company through the anticipated upcoming international Phase 3 trials and global commercialization.

Read More
Leerink starts Clementia at OP

Leerink launched coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with an “outperform” rating and $23 price target. The stock closed at $16.11 on August 25.

Read More
Stifel ups Reata price target to $50

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.

Read More
Leerink starts Dova at MP

Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21.

Read More
Stifel upgrades Durect to buy

Stifel upgraded Durect (NASDAQ:DRRX) to “buy” from “hold” and raised its price target to $3 from $1.25 and also transitioned coverage to Adam Walsh from Annabel Samimy. The stock closed at $1.59 on July 11.

Read More
HCW starts Tetraphase at buy

H.C. Wainwright initiated coverage of Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a “buy” rating and $15 price target. The stock closed at $6.88 on July 10.

Read More
HCW starts ObsEva at buy

H.C. Wainwright initiated coverage of Swiss-based ObsEva (NASDAQ:OBSV) with a “buy” rating and $27 price target. The stock closed at $7.50 on June 29.

Read More
Tetra readies Phase 3 pain relief trial of medical cannabis

Tetra Bio-Pharma (CSE:TBP; OTCQB:TBPMF) and subsidiary, PhytoPain Pharma, have submitted a report on the safety and pharmacokinetics of its PPP001 smokeable cannabis product to Health Canada.

Read More
HCW starts ZIOPHARM at buy

H.C. Wainwright initiated coverage of ZIOPHARM Oncology (NASDAQ:ZIOP) with a “buy” rating and $9.50 price target. The stock closed at $5.85 on May 31.

Read More
WB starts Biohaven at OP

William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26.

Read More